We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SEC Advisory Panel May Not Influence Sarbanes-Oxley Decisions
SEC Advisory Panel May Not Influence Sarbanes-Oxley Decisions
April 28, 2006
The fact that an SEC advisory committee has overwhelmingly recommended that the agency grant relief from Sarbanes-Oxley (SOX) reporting and auditing requirements for small companies may not have the influence on the SEC that the pharmaceutical and biotechnology industries may believe, an agency spokesman says.